Literature DB >> 32458635

Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on Clinical Behavior of Medullary Thyroid Carcinoma.

Vasudha Mishra1,2, Pradnya Kowtal1,2, Pallavi Rane3, Rajiv Sarin1,2,4.   

Abstract

BACKGROUND: Role of RET proto-oncogene as predisposing gene for Medullary Thyroid Carcinoma is well established which provides the basis for clinical management of patients. However clinical behavior of MTC varies considerably among patients. Several studies have investigated whether SNPs in low penetrance genes could modulate the clinical behavior of MTC but with conflicting or inconclusive results. The present study aimed to investigate the modifier effect of 13 SNPs of three distinct genetic pathways -Detoxification, Cell cycle regulation and RET on the clinico-pathological features of hereditary and sporadic MTC.
METHODS: SNPs were genotyped using RFLP or TaqMan method. The genotypes were correlated with various clinico-pathological parameters (age and calcitonin levels at MTC diagnosis, tumor volume, nodal and distant metastasis).
RESULTS: Nodal metastasis was the only clinico-pathological parameter showing significant association with any SNP. In the hereditary MTC group (n=77), incidence of nodal metastases was significantly higher in wild type allele for Cyp1A1m1, CDKN2A and CDKN2C (p=0.01 for all three). In sporadic MTC group (n=361) CDKN2C wild type allele had higher nodal metastasis (p=0.03).
CONCLUSION: In this largest MTC cohort with comprehensive analysis of modulatory role of 13 most frequently studied SNPs with MTC clinical outcome, we observed a statistically significant association of few SNPs with nodal metastasis. However as these SNPs did not show association with any other clinico-pathological parameters like tumor volume or Calcitonin, they may not be true modifier of MTC. Additional large cohort studies with clinico-pathological details and long-term follow-up are needed to identify genetic modifiers of MTC behavior.

Entities:  

Keywords:  Association-study; MTC; Medullary thyroid carcinoma; RET; SNP

Mesh:

Substances:

Year:  2020        PMID: 32458635      PMCID: PMC7541877          DOI: 10.31557/APJCP.2020.21.5.1289

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  22 in total

1.  The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland.

Authors:  Maria Sromek; Malgorzata Czetwertyńska; Elzbieta Skasko; Joanna Zielińska; Dorota Czapczak; Jan Steffen
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

2.  Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation.

Authors:  Rosana Tamanaha; Cléber P Camacho; Alexandre C Pereira; Adriana M Alvares da Silva; Rui M B Maciel; Janete M Cerutti
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-05       Impact factor: 3.478

3.  Polymorphisms of cell cycle control genes influence the development of sporadic medullary thyroid carcinoma.

Authors:  R B Barbieri; N E Bufalo; R Secolin; L V M Assumpção; R M B Maciel; J M Cerutti; L S Ward
Journal:  Eur J Endocrinol       Date:  2014-12       Impact factor: 6.664

4.  Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer.

Authors:  Andreas Machens; Karin Frank-Raue; Kerstin Lorenz; Susanne Rondot; Friedhelm Raue; Henning Dralle
Journal:  Clin Endocrinol (Oxf)       Date:  2012-05       Impact factor: 3.478

5.  Genes of detoxification are important modulators of hereditary medullary thyroid carcinoma risk.

Authors:  R B Barbieri; N E Bufalo; L L Cunha; L V M Assumpção; R M B Maciel; J M Cerutti; L S Ward
Journal:  Clin Endocrinol (Oxf)       Date:  2013-08       Impact factor: 3.478

6.  CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma.

Authors:  Daniela Pasquali; Luisa Circelli; Antongiulio Faggiano; Massimo Pancione; Andrea Renzullo; Rossella Elisei; Cristina Romei; Giacomo Accardo; Viviana Raffaella Coppola; Maurizio De Palma; Piero Ferolla; Franco Grimaldi; Annamaria Colao; Vittorio Colantuoni
Journal:  Eur J Endocrinol       Date:  2010-12-21       Impact factor: 6.664

7.  Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A.

Authors:  Mercedes Robledo; Laura Gil; Marina Pollán; Arancha Cebrián; Sergio Ruíz; Marta Azañedo; Javier Benitez; Javier Menárguez; José M Rojas
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

8.  Evidence that polymorphisms in detoxification genes modulate the susceptibility for sporadic medullary thyroid carcinoma.

Authors:  R B Barbieri; N E Bufalo; R Secolin; A C N Silva; L V M Assumpção; R M B Maciel; J M Cerutti; L S Ward
Journal:  Eur J Endocrinol       Date:  2011-11-02       Impact factor: 6.664

9.  RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series.

Authors:  Laura Fugazzola; Marina Muzza; Caterina Mian; Daniela Cordella; Susi Barollo; Luisella Alberti; Valentina Cirello; Davide Dazzi; Maria Elisa Girelli; Giuseppe Opocher; Paolo Beck-Peccoz; Luca Persani
Journal:  Clin Endocrinol (Oxf)       Date:  2008-02-11       Impact factor: 3.478

10.  Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper.

Authors:  Mette Munk Jensen; Jesper Tranekjaer Jørgensen; Tina Binderup; Andreas Kjaer
Journal:  BMC Med Imaging       Date:  2008-10-16       Impact factor: 1.930

View more
  1 in total

1.  Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma.

Authors:  Anna Skalniak; Małgorzata Trofimiuk-Müldner; Elwira Przybylik-Mazurek; Alicja Hubalewska-Dydejczyk
Journal:  Int J Mol Sci       Date:  2021-10-30       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.